Natixis Advisors LLC Acquires 46,229 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Natixis Advisors LLC lifted its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 422.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 57,166 shares of the company's stock after purchasing an additional 46,229 shares during the quarter. Natixis Advisors LLC's holdings in Dr. Reddy's Laboratories were worth $903,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of RDY. EverSource Wealth Advisors LLC boosted its stake in Dr. Reddy's Laboratories by 423.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock valued at $29,000 after purchasing an additional 1,507 shares in the last quarter. POM Investment Strategies LLC boosted its stake in Dr. Reddy's Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after buying an additional 1,820 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in Dr. Reddy's Laboratories by 461.0% during the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock worth $40,000 after acquiring an additional 2,093 shares during the period. Allworth Financial LP raised its position in Dr. Reddy's Laboratories by 447.8% in the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company's stock worth $41,000 after acquiring an additional 2,230 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new stake in Dr. Reddy's Laboratories in the 4th quarter valued at about $43,000. Institutional investors and hedge funds own 3.85% of the company's stock.

Remove Ads

Dr. Reddy's Laboratories Stock Down 0.6 %

Shares of NYSE RDY traded down $0.08 during mid-day trading on Friday, reaching $13.20. The company had a trading volume of 2,048,621 shares, compared to its average volume of 1,317,508. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The company has a market capitalization of $11.01 billion, a price-to-earnings ratio of 21.01 and a beta of 0.48. The stock has a fifty day moving average of $13.48 and a two-hundred day moving average of $14.60. Dr. Reddy's Laboratories Limited has a 12-month low of $12.50 and a 12-month high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, equities research analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on RDY shares. StockNews.com lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, December 6th. Nomura cut Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.